Ascendia

  MARKET NEWS

NodThera Announces Positive First-in-Human Data for Two Brain Penetrant NLRP3 Inflammasome Inhibitors
Ashland Announces Multifunctional Disintegrant for Improved Pharmaceutical Process Throughput
Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV & hMPV in Older Adults
ANAVEX2-73 (blarcamesine) Receives Compassionate Use Authorization for Pediatric Patients With Rett Syndrome
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b Trial of Rencofilstat
Ventyx Biosciences Announces Initiation of Dosing in Phase 1 Trial of  Novel CNS-Penetrant NLRP3 Inhibitor

  FEATURED EDITORIAL

  COMPANY PROFILE

Resilience is a technology-focused manufacturing company dedicated to broadening access to complex medicines. Founded in 2020, the company is building a network of high-tech, end-to-end manufacturing solutions with the aim of ensuring that the medicines of today and tomorrow can be made quickly, safely, and at scale. By continuously advancing the science of biopharmaceutical manufacturing and development, Resilience aims to free partners to focus on the discoveries that improve patients’ lives and protect biopharmaceutical supply chains against future disruptions. Click here to learn more.

  EXCLUSIVE ONLINE CONTENT

Croda Announces Two New Partnerships to Drive Sustainable Delivery Systems for the Pharmaceutical Industry

Croda Announces Two New Partnerships to Drive Sustainable Delivery Systems for the Pharmaceutical Industry

Croda International Plc recently announced it has signed two new partnership agreements that will help the pharmaceutical industry move toward a more sustainable supply chain for vaccine adjuvants…..

Curia Expands Cell Line Development Offering With CHOZN Platform

Curia Expands Cell Line Development Offering With CHOZN Platform

Curia signs license agreement with MilliporeSigma to support production of proteins and antibodies….

Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology

Thaerapy BV & Resyca BV Announce Exclusive License Agreement for Soft Mist Inhaler Technology

Thaerapy BV and Resyca BV a joint venture of Medspray Pharma BV and Recipharm AB, a leader in the development of soft mist inhalers, recently announced today the signing of an exclusive license agreement for Resyca’s soft mist….

Celanese & Nanoform Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants

Celanese & Nanoform Demonstrate Enhanced Drug Delivery Through the Power of Smaller Implants

Celanese and Nanoform Finland Plc recently provided an update on their collaboration to evaluate the synergies between their respective technologies in the field of nanoparticle-enabled drug delivery…..

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas

Blue Water Biotech, Inc. recently announced the signing of an Asset Purchase Agreement with WraSer, LLC and Xspire Pharma, LLC for the purchase of six FDA-approved assets across multiple indications, including cardiology, otic infections, and pain….

  WHITEPAPERS & WEBINARS

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

ON-DEMAND WEBINAR – Solve Common Design Challenges in Inhalation Devices With Porous Polymers

The effectiveness of inhalation devices relies on their ability to deliver the pharmaceutical directly to the targeted part of the body with precision and calculated dosing.  Since these devices….

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

ON-DEMAND WEBINAR - Exploring Pectin & the Advancement of Delayed Release Technology

In this webinar, experts will provide an overview of why the properties and structure of pectin are well suited for site-specific delivery to the colon. In addition, experts will also provide insights into how softgel capsules, formed by the combination of both pectin and gelatin, are used in OptiGel® DR, a new delayed release delivery technology for pharmaceutical applications.

  WHITEPAPERS & WEBINARS

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

WHITEPAPER - Enhancing the Solubility of Active Pharmaceutical Ingredients Using Hot Melt Extrusion & Polyvinyl Alcohol

 

Solubility of the active pharmaceutical ingredient (API) in an oral formulation is critical for absorption from the gastrointestinal (GI) tract and the intended therapeutic effect. Ensuring that an API has the necessary solubility can be challenging for drug developers …

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

APPLICATION NOTE: Process Optimization & Preclinical Production Using the ANP System

Particle Works is thrilled to announce the launch of a new Application Note that delves into the advancement of nanoparticles as carriers for targeted drug delivery. Developing nanoparticles for this purpose can be intricate and demanding, necessitating consistent, cost-effective, and …

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

TECH BRIEF – Expedite FDA Approvals With Certified Pure Materials

A key focus of the U.S. Food and Drug Administration’s evaluation of a medical device’s safety and effectiveness is reviewing its material makeup. If improperly tested – and impure materials are used – there is an elevated risk of contamination …

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

WHITEPAPER - How to Mitigate Risk for Biologics During Fill/Finish Manufacturing

Aseptic processing with the highest degree of sterility assurance, filling accuracy, and quality is critical for high-value, small-batch therapies. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing.

CLICK HERE TO DOWNLOAD/VIEW THE …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June – 28 – Excipients
July 5 – Controlled Release